Response to Coronavirus Queries both Internationa
Post# of 9144
(Total Views: 340)
Posted On: 02/28/2020 11:32:38 AM
Response to Coronavirus Queries both International and US
The Company continues to receive calls inquiring about Coronavirus (COVID-19) testing capabilities.
While we believe our technology could be used to develop a rapid test for the Coronavirus, based upon preliminary development work done for detection of proteins associated with Ebola in 2014, we do not have the resources to pursue development of a Coronavirus rapid test. There are a small number of BioSafety Level 4 labs in the US (4+/-) where development work on dangerous viruses can be done and their calendars are booked months to years in advance with daily costs that can run into tens of thousands of dollars. The Coronavirus may be a short-lived phenomenon that is no longer an issue within a few months; there are other tests that exist that may deliver reliable results in a few hours or a day, and while a test we develop may potentially deliver results in minutes, it may not be viewed as worthwhile in a cost:benefit analysis by various agencies or institutions.
In conclusion, we are fully committed to our current work on Urinary Tract and Yeast Infections rapid detection development utilizing a unique screening test and our N-Assay modified ELISA process.
The Company continues to receive calls inquiring about Coronavirus (COVID-19) testing capabilities.
While we believe our technology could be used to develop a rapid test for the Coronavirus, based upon preliminary development work done for detection of proteins associated with Ebola in 2014, we do not have the resources to pursue development of a Coronavirus rapid test. There are a small number of BioSafety Level 4 labs in the US (4+/-) where development work on dangerous viruses can be done and their calendars are booked months to years in advance with daily costs that can run into tens of thousands of dollars. The Coronavirus may be a short-lived phenomenon that is no longer an issue within a few months; there are other tests that exist that may deliver reliable results in a few hours or a day, and while a test we develop may potentially deliver results in minutes, it may not be viewed as worthwhile in a cost:benefit analysis by various agencies or institutions.
In conclusion, we are fully committed to our current work on Urinary Tract and Yeast Infections rapid detection development utilizing a unique screening test and our N-Assay modified ELISA process.
(2)
(0)